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While it had long been known that des-
mosomes were crucial for interconnect-
ing cells in laboratory experiments, the 
link between desmosomal adhesion 
and human health was bolstered by sev-
eral key experiments demonstrating that 
desmogleins were targeted in both auto-
immune and infectious diseases. In two 
landmark papers authored by  Masayuki 
Amagai working with John Stanley, des-
mogleins 1 and 3 (Dsg1 and Dsg3) were 
confirmed as molecular targets in staph-
ylococcal scalded skin syndrome (SSSS) 
and pemphigus vulgaris (PV), respec-
tively. These noteworthy discoveries 
constitute a milestone in the science of 
desmosomes as they drew considerable 
attention to the connection between the 
so-called intercellular “spot welds” and 
specific human diseases.
PV was originally described as a 
blistering disease characterized by 
splitting of the epidermis near its basal 
layer, a life-threatening consequence 
for patients. The molecular mechanism 
of PV remained elusive for many years, 
but it was discovered in 1982 by Anhalt 
and colleagues that PV could be pheno-
copied in mice by passive transfer of IgG 
from humans suffering from active PV, 
confirming the role of pathogenic anti-
bodies (PV-IgG) in the disease. Although 
this report established that PV-IgG was 
sufficient to cause a PV-like disease in 
an animal model, the molecular target 
of these antibodies remained a mystery 
until 1991, when Amagai et al. (1991) 
successfully cloned as gene encoding 
a protein specifically recognized by 
autoantibodies present in human PV 
sera. Using PV-IgG to screen a keratino-
cyte expression library, the investigators 
deciphered the amino-acid sequence 
of the 130 kDa PV antigen (PVA). The 
authors reported significant homol-
ogy of PVA with cadherins, most nota-
bly Dsg1, which had previously been 
identified as a target of antibodies in 
another autoimmune blistering disease, 
pemphigus foliaceus (PF) (Stanley et al., 
1986). The conclusion that the PV anti-
gen was a novel desmosomal cadherin 
(later named Dsg3) supported an ear-
lier demonstration by Jones et al. (1984) 
that PV-IgG targeted the desmosome. 
Also, given the expression pattern of the 
novel cadherin in stratified epithelia, 
particularly the skin and mucous mem-
branes, an explanation for the localiza-
tion of blisters in PV and PF began to 
emerge (Figure 1). Thus, through a for-
ward genetics approach utilizing patho-
genic antibodies from patients, Amagai 
and colleagues established a role for a 
novel desmosomal component in the 
pathogenesis of a devastating human 
skin disease.
In 2000, the team of Amagai and 
Stanley provided the pathogenic expla-
nation of a distinct epidermal blister-
ing disease caused by exfoliative toxin 
A (ETA) produced by Staphylococcus 
aureus. Bacterial isolates from lesions 
in the common blistering disease, bul-
lous impetigo, or the more advanced 
SSSS reliably produce ETA, a toxin sus-
pected to have serine protease activity 
based on structural analysis. Injection 
of this toxin into mice was sufficient to 
induce acantholysis in the superficial 
epidermis (Melish and Glasgow, 1970), 
yet its substrate remained unknown 
for many years. Interestingly, it had 
previously been noted that epidermal 
Figure 1. Desmogleins are targeted in epidermal blistering diseases. Dsg1 is expressed most highly 
in the superficial epidermis, whereas Dsg3 is more restricted to the lower layers. (Left) In pemphigus 
vulgaris (PV), autoantibodies (PV-IgG) bind Dsg3 and result in splitting near the basal layer of the 
epidermis. (Right) Binding of Dsg1 by PF-IgG in pemphigus foliaceus (PF) or cleavage by ETA in 
staphylococcal scalded skin syndrome (SSSS) leads to superficial acantholysis.
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samples from PF patients with anti-Dsg1 
antibodies looked identical to histo-
logical specimens from patients suffer-
ing from SSSS. This shared phenotype 
led Amagai and co-workers to investi-
gate whether Dsg1 was a substrate for 
ETA. Through in vitro and in vivo stud-
ies, the investigators confirmed that 
exposure of cultured keratinocytes or 
mice to ETA produced Dsg1 degrada-
tion and showed direct cleavage of the 
Dsg1 ectodomain in solution, whereas 
the similar cadherin, Dsg3, remained 
intact (Amagai et al., 2000). The toxin’s 
exquisite specificity explained why 
ETA-induced blisters are always limited 
to the superficial epidermis, where the 
target, Dsg1, is most highly expressed 
and required for resisting mechani-
cal stress (Figure 1). This conclusion 
advanced our understanding of bullous 
impetigo and SSSS pathogenesis and 
once again brought the desmosome to 
the forefront of molecular medicine.
Given the prevalence of desmo-
somes in the stratified epidermal lay-
ers, it was not surprising that the 
adhesive function of desmogleins 
was compromised in diseases char-
acterized by acantholysis among epi-
dermal keratinocytes. However, the 
finding that the desmosome was the 
common molecular denominator of 
two dermatologic diseases of distinct 
etiologies was a significant scientific 
achievement. By firmly establishing 
the role of desmosomes in human 
disease, these discoveries by Amagai, 
Stanley and co-workers paved the way 
for the myriad publications that have 
followed, each advancing our under-
standing of pathologies that result from 
disrupting these all-important adhe sive 
structures.
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